- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eli lilly (LLY)
Assess today's live Eli lilly (LLY) share price, performance and insights using our live NYSE: LLY stock exchange data.
Analyse the historical data and Eli lilly share price performance charts on this page. Our technical summary section provides analysis on Eli Lilly share price buy/sell indicators using real-time data (or discuss the Eli Lilly (LLY) stock price today with other investors in the Eli Lilly NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE LLY share price (ISIN: US5324571083) to enhance your trading decisions with our free investment tools and resources.
What Is the Eli lilly Share Price Today?
The Eli Lilly share price today is 715.20.
What Is the Stock Symbol for Eli lilly
The stock symbol (or 'ticker') for Eli lilly & Company is "LLY."
What Stock Exchange Does Eli lilly Trade On?
Eli lilly & Company is listed and trades on the NYSE stock exchange.
Is Eli lilly a Good Stock to Buy?
Determining whether Eli lilly & Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Eli lilly share price performance charts on this page. Our technical summary section provides analysis on Eli Lilly share price buy/sell indicators using real-time data (or discuss the Eli Lilly (LLY) stock price today with other investors in the Eli Lilly NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE LLY share price (ISIN: US5324571083) to enhance your trading decisions with our free investment tools and resources.
What Is the Eli lilly Share Price Today?
The Eli Lilly share price today is 715.20.
What Is the Stock Symbol for Eli lilly
The stock symbol (or 'ticker') for Eli lilly & Company is "LLY."
What Stock Exchange Does Eli lilly Trade On?
Eli lilly & Company is listed and trades on the NYSE stock exchange.
Is Eli lilly a Good Stock to Buy?
Determining whether Eli lilly & Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
715.20
-9.75(-1.34%)
Closed·
Pre Market
711.83-3.37(-0.47%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
711.55
722.19
52 wk Range
677.09
972.53
LLY Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
LLY is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
711.55722.19
52 wk Range
677.09972.53
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.84%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.84%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LLY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
955.01
Upside
+33.53%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
7 analysts have revised their earnings upwards for the upcoming period
- Organon Co receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Organon Co receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Eli Lilly Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company SWOT Analysis
GLP-1 Market Leade | Eli Lilly dominates the GLP-1 category with Mounjaro and Zepbound, showcasing strong growth in prescriptions and market share against key competitors |
Global Expansion | Explore Eli Lilly's strategy to tap into ex-US markets, representing 90% of projected long-term volume for GLP-1 treatments, driving significant future growth |
Pipeline Potential | Delve into Eli Lilly's promising pipeline, including Orforglipron, an oral GLP-1 treatment that could revolutionize the market with its convenience and efficacy |
Financial Outlook | Analysts set price targets ranging from $970 to $1,250, reflecting optimism about Eli Lilly's 2025 revenue guidance of $58-$61 billion and robust 32% topline growth |
Eli Lilly and Company Earnings Call Summary for Q1/2025
- Q1 revenue up 45% YoY to $12.73B, driven by key products; EPS of $3.34 missed $3.46 forecast
- Stock dropped 8.56% post-earnings; company trades above Fair Value per InvestingPro analysis
- Gross margin improved to 83.5%; non-GAAP performance margin up 11+ points to 42.6%
- Full-year revenue guidance reaffirmed; phase 3 data for orforglipron expected by end of 2025
- CEO highlighted promising Achieve One trial results, increased U.S. manufacturing investments
Last Updated: 01/05/2025, 16:18
Read Full TranscriptCompare LLY to Peers and Sector
Metrics to compare | LLY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLLYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 57.8x | −1.3x | −0.4x | |
PEG Ratio | 0.71 | 0.00 | 0.00 | |
Price/Book | 40.7x | 1.8x | 2.6x | |
Price / LTM Sales | 13.1x | 3.3x | 2.9x | |
Upside (Analyst Target) | 36.3% | 46.1% | 53.5% | |
Fair Value Upside | Unlock | 15.8% | 9.5% | Unlock |
Analyst Ratings
22 Buy
5 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 955.01
(+33.53% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
3.34 / 3.46
Revenue / Forecast
12.73B / 12.72B
People Also Watch
FAQ
What Is the Eli Lilly (LLY) Stock Price Today?
The Eli Lilly stock price today is 715.20
What Stock Exchange Does Eli Lilly Trade On?
Eli Lilly is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Eli Lilly?
The stock symbol for Eli Lilly is "LLY."
Does Eli Lilly Pay Dividends? What’s The Current Dividend Yield?
The Eli Lilly dividend yield is 0.84%.
What Is the Eli Lilly Market Cap?
As of today, Eli Lilly market cap is 642.06B.
What Is Eli Lilly's Earnings Per Share (TTM)?
The Eli Lilly EPS (TTM) is 12.34.
When Is the Next Eli Lilly Earnings Date?
Eli Lilly will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is LLY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Eli Lilly Stock Split?
Eli Lilly has split 5 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.